Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg. In this regard, the company has enclosed its press release.
The above information is a part of company’s filings submitted to BSE.